rucotinib phosphate

Rucotinib phosphate is a Janus kinase (JAK) inhibitor that selectively targets JAK1 and JAK2. It is a phosphate salt formulation of the small molecule rucotinib, which is a phonetic variant of the international nonproprietary name (INN) ruxolitinib. Primarily developed as a topical cream, rucotinib phosphate is utilized for the treatment of dermatological conditions, most notably non-segmental vitiligo. By inhibiting the JAK-STAT signaling pathway, the drug reduces the activity of pro-inflammatory cytokines such as interferon-gamma (IFN-γ), which are implicated in the autoimmune-mediated destruction of melanocytes. Clinical studies, including real-world cohort evaluations in China, have focused on its effectiveness in promoting repigmentation and improving psychosocial outcomes in both adolescents and adults with facial vitiligo.

Other names

rucotinibruxolitinib phosphateruxolitinibrucotinib phosphate cream